Last update 21 Nov 2024
SAR444200
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Nanobody |
Synonyms |
Target |
Mechanism GPC3 inhibitors(Glypican-3 inhibitors), TCR antagonists(T-cell receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with SAR444200一项在晚期实体瘤患者中评估 SAR444200 给药方案的安全性、药代动力学、药效动力学和抗肿瘤活性的Ⅰ/Ⅱ期、开放性、首次人体、剂量递增和扩展研究。
[Translation] A Phase I/II, open-label, first-in-human, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a dosing regimen of SAR444200 in patients with advanced solid tumors.
A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors.
100 Clinical Results associated with SAR444200
Login to view more data
100 Translational Medicine associated with SAR444200
Login to view more data
100 Patents (Medical) associated with SAR444200
Login to view more data
100 Deals associated with SAR444200
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | US | 20 Sep 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 20 Sep 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | KR | 20 Sep 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | SG | 20 Sep 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CA | 20 Sep 2022 | |
| GPC3 Positive Neoplasms | IND Approval | CN | 09 Jul 2023 | |
| GPC3 Positive Neoplasms | IND Approval | CN | 09 Jul 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Advanced Malignant Solid Neoplasm interleukin-6 | interferon gamma | alpha-fatal protein (AFP) | 24 | (tykmjxkljz) = 2 events with hospitalization prolongation for a Grade 1 and 2 cytokine release syndrome [CRS] that recovered completely without and with Tocilizumab, respectively, 1 event with pneumonitis Grade 3 cnnwndycjc (fnfbhaauas ) View more | Positive | 24 May 2024 | ||
SAR444200 1 mg |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free